Clinical Trials Logo

Bleeding clinical trials

View clinical trials related to Bleeding.

Filter by:

NCT ID: NCT06328647 Not yet recruiting - Bleeding Clinical Trials

Quantra Point-of-Care Hemostasis Monitoring

QUANTRA
Start date: April 1, 2024
Phase: N/A
Study type: Interventional

The investigators will test the hypothesis that utilization of a blood and blood component transfusion algorithm guided by the POC Quantra QPlus System in patients undergoing complex cardiac surgery will reduce RBC, plasma, cryoprecipitate, and platelet transfusion during surgery and the first 12 postoperative hours, compared to standard of care (central laboratory transfusion monitoring at the primary anesthesia provider's discretion).

NCT ID: NCT06301204 Completed - Bleeding Clinical Trials

Effectiveness Of Tranexamic Acıd Application Wıth Different Doses On Bleeding, Edema And Physician Comfort In Orthognathıc Surgery Patients

Start date: March 1, 2022
Phase: N/A
Study type: Interventional

The aim of this clinical study conducted in accordance with the information in the literature is to compare the effects of administering tranexamic acid during orthognathic surgery, at different doses. Specifically, investigators aim to compare the effects of administering 1 ampoule IV (approximately 3 mg/kg) and 2 ampoules IV (approximately 6 mg/kg), and evaluate their impact on intraoperative bleeding (ml), surgical duration (min), postoperative swelling, and intraoperative surgical field evaluation (Fromme Scale), by comparing them with control group (applying no drug administration) patient data.

NCT ID: NCT06299046 Completed - Prostate Cancer Clinical Trials

Bleeding After Robot-assisted Radical Prostatectomy: a Respective Study

UROBLOOD01
Start date: December 1, 2022
Phase:
Study type: Observational

Nowadays robot-assisted radical prostatectomy (RARP) has become the standard surgical treatment for localised prostate cancer. The robotic approach has been proven superior to open retropubic prostatectomy (ORP) in terms of surgical-related morbidity: RARP has in fact been associated with significantly lower estimated blood loos (EBL), lower transfusion rate, less length of stay, shorter catheterization time, lower risk of Clavien-Dindo grade II and III complications, lower risk of vesicourethral anastomotic stricture and less post-operative pain. The optimal anatomical visualisation and the extraordinary maneuverability, along with the tamponade effect of the pneumoperitoneum, are surely to be deemed responsible of this statistically significant differences. However, to this day no study has ever investigated the prognostic significance of haematological parameters in terms of predicting perioperative bleeding risk in patients undergoing RARP. Therefore, the investigators conducted a retrospective non-interventional cohort study to gather evidence concerning the impact of anemia and thrombocytopenia on bleeding risk following this surgical procedure. Furthermore, the investigators evaluated associations between demographical, pathological and surgical factors and hemorrhagic complications. The investigators retrospectively evaluated all the patients that underwent robot-assisted radical prostatectomy in our Urology Unit from the 1st of January 2017 to the 31th of December 2020. The investigators collected demographic, clinical and pathological data from the medical records of these patients, with particular attention to other known risk-factors for RARP-associated bleeding (e.g.: volume of the prostate, body mass index, smoking status, nerve sparing technique). Complications were analyzed according to the Clavien- Dindo classification. Bleeding was assessed by considering both the hemoglobin (Hb) drop after surgery and the fluid intraoperatively collected in the suction canister, with all the due adjustments. Moreover, post-operative haemorrhagic complications were evaluated. The investigators included patients not younger than 18 years old, of which records of a pre-operative full blood count in the 30 days prior to the surgery along with a full blood count the day after were available. Criteria for exclusion were a history of congenital coagulopathies and/or congenital thrombocytopenia and patients that underwent salvage radical prostatectomy after radiation therapy. Statistics: EBL and operative time learning curve is studied. Clinical, pathological, intraoperative risk factors analysis for higher EBL is performed by linear regression modelling. Factors are evaluated independently and jointly. Association between each factor above and post-operative outcomes (i.e. post-op bleeding, need of transfusion and hematuria) is also assessed.

NCT ID: NCT06245746 Not yet recruiting - Clinical trials for Acute Myeloid Leukemia

UCMSC-Exo for Chemotherapy-induced Myelosuppression in Acute Myeloid Leukemia

Start date: March 2024
Phase: Phase 1
Study type: Interventional

The purpose of the study is to explore the safety and efficacy of UCMSC-Exo in consolidation chemotherapy-induced myelosuppression in patients with acute myeloid leukemia after achieving complete remission.

NCT ID: NCT06242353 Not yet recruiting - Clinical trials for Acute Lymphoblastic Leukemia

Coagulopathy in Childhood Acute Lymphoblastic Leukaemia

CoagCALL
Start date: March 1, 2024
Phase:
Study type: Observational

The goal of this study is to investigate the hemostatic balance in children with acute lymphoblastic leukaemia (ALL) treated according to the ALLTogether1 protocol with focus on the early treatment period including concomitant use of steroids and asparaginase. The investigators aim to determine if complement proteins or microparticles can be used as clinically relevant predictive or diagnostic biomarkers for thrombosis and if global hemostatic assays can predict bleeding or thrombosis. Characterization of proteins connected to hemostasis before and during ALL treatment may provide pathophysiological insights regarding ALL- and treatment related coagulopathy. The ultimate goal of the study is to minimize the morbidity and mortality related to thrombosis and bleeding complications in children with ALL. Several pediatric oncology centers in Sweden will be participating in this study, which will enroll approximately 100 pediatric patients.

NCT ID: NCT06229483 Not yet recruiting - Brain Tumor Clinical Trials

The Effects of Intraoperative Tranexamic Acid on Perioperative Bleeding In Craniotomies

Start date: March 2024
Phase: Phase 3
Study type: Interventional

The goal of this clinical trial is to test the effect of a drug called tranexamic acid (TXA) on reducing blood loss in participants undergoing surgery to remove brain tumors. The main questions it aims to answer are: 1. Does TXA reduce the amount of estimated blood loss during surgery? 2. Does TXA prevent re-operation, disability or death related to bleeding inside the head during and after surgery? Participants are randomized to receive 1 g of TXA or Placebo (0.9 normal saline) within 30 minutes prior to beginning of surgery. Treatment allocation is blinded. Investigator will compare the two treatment arms to see whether there are differences in the amount of blood loss during surgery and bleeding-related complications. Investigators will also monitor for any side effects of TXA.

NCT ID: NCT06220149 Not yet recruiting - Bleeding Clinical Trials

Post Polypectomy Bleeding. Que Sera, Sera? Whatever Will be, Will be?

FILLIP
Start date: January 2024
Phase:
Study type: Observational

Patients with colorectal polyps removed endoscopically (polypectomy, endoscopic mucosal resection, underwater endoscopic mucosal resection, endoscopic submucosal dissection) may experience delayed post polypectomy bleeding. The incidence is about one in 40 cases. There are risks factors for this complication, depending on the polyp type, patient demographics and co-morbidities and polypectomy technique. There are meta-analysis and nomograms for risk prediction available. We will try to predict delayed post polypectomy bleeding by using FIT (fecal immunochemical test), with a cut-off adapted to detect post polypectomy bleeding, administered daily for 2 weeks after polypectomy.

NCT ID: NCT06219668 Completed - Bleeding Clinical Trials

Comparison of Omentopexy and Clips on the Staple Line During Laparoscopic Sleeve Gastrectomy

Start date: August 15, 2023
Phase: N/A
Study type: Interventional

Background: Bleeding through the staple line has been reported as one of the most common staple-related complications in laparoscopic sleeve gastrectomy (LSG). In this study, we aimed to compare the effects of clips and omentopexy techniques on postoperative bleeding and readmissions during the first 30-days following surgery. Methods: In this prospective randomized controlled study, patients were divided into two groups: clips group and omentopexy group. The groups were compared in terms of postoperative decrease in hemoglobin and hematocrit values, preoperative and peroperative blood pressure values, duration of surgery, number of patients requiring erythrocyte suspension (ES) transfusion, length of hospital stay, hospital readmissions in the first 30-days postoperatively and early postoperative complications.

NCT ID: NCT06211699 Completed - Clinical trials for Postoperative Complications

Effect of Clips Versus Omentopexy on Postoperative Bleeding

Start date: July 1, 2023
Phase: N/A
Study type: Interventional

In this prospective randomized study, patients were divided into two groups: clips group and omentopexy group. The groups were compared in terms of postoperative decrease in hemoglobin and hematocrit values, preoperative and peroperative blood pressure values, duration of surgery, number of patients requiring erythrocyte suspension (ES) transfusion, length of hospital stay, hospital readmissions in the first 30-days postoperatively and early postoperative complications.

NCT ID: NCT06187831 Recruiting - Bleeding Clinical Trials

Bleeding Events Before vs After Lowering Departmental Platelet Transfusion Trigger

OBS-PLATE
Start date: February 26, 2024
Phase:
Study type: Observational [Patient Registry]

Central venous catheters are essential when administering treatment for hematological conditions. Many patients have a decreased platelet count which increases the risk for bleeding complications. Baarle et al. recently published a randomized controlled study where withholding prophylactic platelet transfusions before CVC placement in patients with a platelet count of 10,000 to 50,000 per cubic millimeter did not meet the predefined margin for non-inferiority for postprocedural bleeding events (PMID: 37224197). However, bleedings grade 2 (defined as bleeding that requires external compression) were included despite lacking clinical significance. The aim of the present study is to investigate whether lowering the preprocedural platelet transfusion trigger from 50x10^9/L to 10x10^9/L for insertions of central venous catheters remains safe with regards to postprocedural bleeding events of grade 3-4.